Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

What will be ZEPATIER real world cure rate in Canada if RAV screening is not required?

From Canadian PRODUCT MONOGRAPH:

GT1a SVR was achieved in 98% (432/439) of subjects without baseline NS5A polymorphisms and 55% (16/29) of subjects with baseline NS5A polymorphisms that confer greater than 5-fold reduction of elbasvir antiviral activity in vitro. Among treatment experienced subjects, SVR was achieved in 99% (291/295) of subjects without baseline NS5A polymorphisms and 50% (13/26) of subjects with baseline NS5A polymorphisms

Genotype 1b SVR was achieved in 100% (223/223) of subjects without baseline NS5A polymorphisms and 86% (31/36) of subjects with baseline NS5A polymorphisms